Key Stories from the past week: China Stimulus Ignites Markets

Key Stories from the past week: China Stimulus Ignites Markets

Macro
Saxo Be Invested
Saxo

Markets have been moving this week after Beijing announced its biggest stimulus since the pandemic in an effort to re-ignite the economic slowdown and subsequent deflation which has plagued China - one of the world largest economies - for a while. Global equities & Precious metals seemed to overall welcome the news with several sectors rallying, especially luxury groups LVMH & Kering trading up on optimism that the stimulus might revive otherwise weakened demand. The Yen has been on a rollercoaster session ahead of Japan's LDP vote and hiking process pressures, and we saw danish pharma giant Novo-Nordisk hit a 6-month low on concerns over competition and pricing. Read more about this week's key stories below:

Hang Seng leaps as China adds to stimulus
After months of economic weakness and speculation the PBOC stepped in and took a more aggressive approach with a number of measures in support of the economy as well as the stock market. This includes among other cutting the 7-day reverse repo rate cut by 20bps, cutting the MLF by 30bps, lower mortgage rates doe existing loads and 500B yuan liquidity support for Chinese stocks. This added on to the risk sentiment that gave way following a 50bps cut by Fed. At Saxo we saw this translated into an increase in number of clients exposed to Hong Kong index by some 10% with 77% of clients being long. 
China’s Bold Stimulus Measures: What It Means for Markets

Novo Nordisk pressured on pricing
Novo Nordisk share price hit a 6-month low and is down almost 20% over the last 10 weeks following the slightly disappointing Q2 results. This week CEO Lars Fruergaard testified in front of the US Senate health committee and that gave rise to more drug-pricing headline noise. Fruergaard promised price cuts, but only if the benefit goes to consumers and not the insurance companies. However, Novo Nordisk continue to hold massive longer term potential and key stock price catalyst in the near term include Rybelsus cardiovascular data and late-stage CagriSema data, which is key to upholding the obesity lead vs. Eli Lilly.

Yen surge after Japan PM election
The yen surged to the upper 142 range against the U.S. dollar after Shigeru Ishiba won Japan's ruling party election, defeating Sanae Takaichi. Ishiba's victory, which positions him to become Japan's next prime minister, led to a brief jump in JPY . Ishiba supports normalizing Japan's monetary policy, causing the yen to strengthen and raising concerns in the stock market due to his stance on financial income taxation.

Next week markets will be monitoring key US jobdata incl. Jobless/continuing claims (Thu), general unemployment & non-farm payrolls (Fri), while also keeping an eye at German inflation data (Mon) & euro area core cpi estimates (Tue). Sports-retail giant Nike that recently named a new CEO is expected to release Q1 25 earnings on Tuesday.


Quarterly Outlook

01 /

  • Equity outlook: The high cost of global fragmentation for US portfolios

    Quarterly Outlook

    Equity outlook: The high cost of global fragmentation for US portfolios

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: Commodities rally despite global uncertainty

    Quarterly Outlook

    Commodity Outlook: Commodities rally despite global uncertainty

    Ole Hansen

    Head of Commodity Strategy

  • Upending the global order at blinding speed

    Quarterly Outlook

    Upending the global order at blinding speed

    John J. Hardy

    Global Head of Macro Strategy

    We are witnessing a once-in-a-lifetime shredding of the global order. As the new order takes shape, ...
  • Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Quarterly Outlook

    Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    Quarterly Outlook

    Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    John J. Hardy

    Global Head of Macro Strategy

  • Equity Outlook: The ride just got rougher

    Quarterly Outlook

    Equity Outlook: The ride just got rougher

    Charu Chanana

    Chief Investment Strategist

  • China Outlook: The choice between retaliation or de-escalation

    Quarterly Outlook

    China Outlook: The choice between retaliation or de-escalation

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: A bumpy road ahead calls for diversification

    Quarterly Outlook

    Commodity Outlook: A bumpy road ahead calls for diversification

    Ole Hansen

    Head of Commodity Strategy

  • FX outlook: Tariffs drive USD strength, until...?

    Quarterly Outlook

    FX outlook: Tariffs drive USD strength, until...?

    John J. Hardy

    Global Head of Macro Strategy

  • Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Quarterly Outlook

    Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Althea Spinozzi

    Head of Fixed Income Strategy

None of the information provided on this website constitutes an offer, solicitation, or endorsement to buy or sell any financial instrument, nor is it financial, investment, or trading advice. Saxo Capital Markets UK Ltd. (Saxo) and the Saxo Bank Group provides execution-only services, with all trades and investments based on self-directed decisions. Analysis, research, and educational content is for informational purposes only and should not be considered advice nor a recommendation. Access and use of this website is subject to: (i) the Terms of Use; (ii) the full Disclaimer; (iii) the Risk Warning; and (iv) any other notice or terms applying to Saxo’s news and research.

Saxo’s content may reflect the personal views of the author, which are subject to change without notice. Mentions of specific financial products are for illustrative purposes only and may serve to clarify financial literacy topics. Content classified as investment research is marketing material and does not meet legal requirements for independent research.

Before making any investment decisions, you should assess your own financial situation, needs, and objectives, and consider seeking independent professional advice. Saxo does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

Please refer to our full disclaimer for more details.

Saxo
40 Bank Street, 26th floor
E14 5DA
London
United Kingdom

Contact Saxo

Select region

United Kingdom
United Kingdom

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo is a registered Trading Name of Saxo Capital Markets UK Ltd (‘Saxo’). Saxo is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871. Registered in England & Wales.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.

©   since 1992